• Grace Kim brings two decades’ experience in financial strategy and business development for private and public companies
• She has a deep track record of leveraging high-impact relationships with Wall Street to optimize capital development strategy and maximize long-term value creation
• As an experienced biopharma financial strategy partner with deep executive network across the industry, Dr Kim will contribute the following to achieve MedinCell’s objectives:
– Build strategic positioning and relationships with high profile US biopharma asset management, prominent sell-side and buy-side analysts, and broad life science stakeholders
– Advise and support US financial strategy
– Support business development
“We are very proud to welcome Grace, who is recognized as one of the best US investor relations strategists,” said Christophe Douat, CEO of MedinCell. “I’m already seeing the impact of her actions. She has a deep understanding of the US pharma and biotech capital world. I’m convinced that she will leverage this understanding to support our strategy, increase our visibility, build demand, and create long-term value. We need to build on the burgeoning interest in MedinCell from top tier US pharma and biotech institutional investors that has followed the commercial launch of UZEDY and the recognition of the first-in-class blockbuster potential of mdc-TJK, an olanzapine long-acting injectable also based on MedinCell’s technology, currently in Phase 3.”
“Led by discussions with top US biotech analysts and diligence, I am impressed by MedinCell’s team, recent achievements, and the strong potential of its pipeline of next-evolution products developed to serve unmet medical needs,” said Dr Kim. “MedinCell is among the most promising companies I have reviewed, and it is a great honor to work with the executive team at this critical inflection point.”
Dr Kim has served senior executive roles at public and private companies including Chief Strategy Officer, Head of Investor Relations, and Chief Business Officer. She has also led two biopharma investor relations/corporate development advisories in Senior Vice President and Founder roles – including Burns McClellan, the oldest biotech IR company in the U.S. Companies she has worked with include BeiGene, BioMarin, Cullinan Oncology, Aimmune (Nestlé) and many other biotechs of diverse therapeutic areas, including CNS and oncology. Dr Kim earned a doctorate in pharmacology from the University of Florida with post-doc immunology and graduate studies at the University of Chicago. She was a science writer in her early career and advised on drug analysis via proprietary database. Dr Kim is published in Nature Clinical Oncology and holds an adjunct faculty position at Columbia University.